Myricetin

CAS No. 529-44-2

Myricetin( Cannabiscetin | NSC 407290 )

Catalog No. M14876 CAS No. 529-44-2

Myricetin is produced from the parent compound taxifolin through the (+)-dihydromyricetin intermediate and can be further processed to form laricitrin and then syringetin, both members of the flavonol class of flavonoids.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 33 In Stock
50MG 50 In Stock
100MG 68 In Stock
500MG 158 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Myricetin
  • Note
    Research use only, not for human use.
  • Brief Description
    Myricetin is produced from the parent compound taxifolin through the (+)-dihydromyricetin intermediate and can be further processed to form laricitrin and then syringetin, both members of the flavonol class of flavonoids.
  • Description
    Myricetin is produced from the parent compound taxifolin through the (+)-dihydromyricetin intermediate and can be further processed to form laricitrin and then syringetin, both members of the flavonol class of flavonoids. Dihydromyricetin is frequently sold as a supplement and has controversial function as a partial GABAA receptor potentiator and treatment in Alcohol Use Disorder (AUD). (In Vitro):Myricetin exhibits the scavenging activity towards a number of radicals and ions. It displays poor activity (IC50 value=1.4 mg/mL) in a superoxide dismutase (SOD)-like activity assay. It prevents cancer cell death via apoptosis via regulation of PI3K/Akt and MAPK signalling pathways. Myricetin exhibits antiphotoaging effects by quenching causative free radicals in the skin. Myricetin is able to suppress UVB-induced COX-2 expression in mouse skin epidermal JB6 P+ cells. It inhibits UVB-induced initiation of activator protein-1 and NF-κβ, as well as Fyn kinase activity. Myricetin inhibits viability of SKOV3 ovarian cancer cells in a dose-dependent manner. It induces DNA DSBs and ER stress, which leads to apoptosis in SKOV3 cells. Myricetin inhibits human Hsp70 by more than 80% with IC50 values of 83, 11 and 12 μM, respectively.(In Vivo):Treatment of orthotopic pancreatic tumors with myricetin results in tumor regression and decreases metastatic spread. Exposure to 150 μM myricetin causes 14%, 26%, 5% and 49% inhibition of rabbit platelet aggregation, induced by ADP, arachidonic acid, collagen and PAF, respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Cannabiscetin | NSC 407290
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3Kγ
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    529-44-2
  • Formula Weight
    318.24
  • Molecular Formula
    C15H10O8
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 20 mg/mL warmed (62.84 mM); DMSO: 63 mg/mL (197.96 mM)
  • SMILES
    O=C1C(O)=C(C2=CC(O)=C(O)C(O)=C2)OC3=C1C(O)=CC(O)=C3
  • Chemical Name
    3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Flamini R, et al. Int J Mol Sci. 2013 Sep 27;14(10):19651-69.
molnova catalog
related products
  • Omipalisib

    A highly potent dual inhibitor PI3K/mTOR inhibitor.

  • P110δ-IN-1

    ME-401 is an effective and selective inhibitor of P110δ (IC50: 8.4 nM).

  • PI3Kβ and δ inhibito...

    A potent, highly selective PI3Kβ/δ inhibitor with IC50 of 7.8/5.3 nM respectively.